NASDAQ:FSTX F-star Therapeutics (FSTX) Stock Price, News & Analysis → Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad) Free FSTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.12▼$7.1250-Day Range$4.42▼$7.1252-Week Range$2.07▼$7.12VolumeN/AAverage Volume709,213 shsMarket Capitalization$156.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get F-star Therapeutics alerts: Email Address Ad InvestorPlaceForget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.Click here to see the details. About F-star Therapeutics Stock (NASDAQ:FSTX)F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.Read More Ad InvestorPlaceForget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.Click here to see the details. FSTX Stock News HeadlinesJuly 20, 2023 | dailymail.co.ukAdam22's porn star wife Lena The Plug ADMITS she enjoyed sex with other man MORE than husband'sJuly 12, 2023 | finance.yahoo.comA*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the USApril 17, 2024 | InvestorPlace (Ad)Forget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.July 11, 2023 | dailymail.co.ukTwitch star Amouranth reveals she has been diagnosed with 'late stage ovarian failure' at AGE 29 - after 'shrugging off confusing mental and physical symptoms' for MONTHSJune 26, 2023 | startribune.comDouglas F. MayoJune 2, 2023 | finance.yahoo.comOchre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of DirectorsApril 24, 2023 | sfgate.comF. Murray Abraham apologizes after sexual misconduct allegationsMarch 8, 2023 | businesswire.cominvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.April 17, 2024 | InvestorPlace (Ad)Forget Nvidia, buy this A.I. Stock NowForget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.March 7, 2023 | finanznachrichten.deF-star Therapeutics, Inc.: F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-star Therapeutics surges as buyer Sino Biopharma gains CFIUS approvalMarch 7, 2023 | marketwatch.comF-star Therapeutics Shares Rally After Cfius Clears Takeover >FSTXMarch 7, 2023 | msn.comWhy F-Star Therapeutics Shares Are Moving HigherMarch 7, 2023 | finance.yahoo.comF-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-Star Therapeutics Blasts Up as Merger Deal Goes ThroughMarch 7, 2023 | finance.yahoo.comF-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaMarch 7, 2023 | msn.comF-star Therapeutics surges on report sale to Sino Biopharma close to CFIUS approvalFebruary 25, 2023 | seekingalpha.comF-star Therapeutics jumps as it extends walk date with buyer to `finalize' CFIUS agreementFebruary 25, 2023 | morningstar.comF-star Therapeutics Inc Ordinary SharesFebruary 23, 2023 | msn.comF-star Therapeutics jumps as it extends walk date with buyer to `finalize" CFIUS agreementFebruary 22, 2023 | finance.yahoo.comWhile institutions own 48% of F-star Therapeutics, Inc. (NASDAQ:FSTX), retail investors are its largest shareholders with 49% ownershipFebruary 9, 2023 | msn.comF-star Therapeutics gains after deal termination date with buyer extended againFebruary 8, 2023 | msn.comF-star Therapeutics gains as buyer Sino Biopharma cancels Shanghai listingFebruary 1, 2023 | msn.comF-star Therapeutics up 18% as it extends end date of merger with invoX PharmaJanuary 26, 2023 | finanznachrichten.deF-star Therapeutics, Inc.: invoX Pharma and F-star Therapeutics issue Joint StatementJanuary 26, 2023 | seekingalpha.comFSTX F-star Therapeutics, Inc.January 26, 2023 | msn.comF-star Therapeutics partly pares loss as buyer says in active talks with CFIUS (update)See More Headlines Receive FSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FSTX CUSIPN/A CIK1566373 Webwww.f-star.com Phone441223497400Fax508-381-0347Employees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,280,000.00 Net MarginsN/A Pretax Margin-213.97% Return on Equity-57.08% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$21.17 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book1.51Miscellaneous Outstanding Shares21,980,000Free Float21,279,000Market Cap$156.50 million OptionableNot Optionable Beta0.85 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesEliot Richard ForsterPresident, Chief Executive Officer & DirectorDarlene M. Deptula-HicksChief Financial Officer, Treasurer & SecretaryLouis KayitalireChief Medical OfficerNeil BrewisChief Scientific OfficerJames SandyChief Development OfficerKey CompetitorsIncannex HealthcareNASDAQ:IXHLCervoMedNASDAQ:CRVOSkye BioscienceNASDAQ:SKYERenovaroNASDAQ:RENBSpyre TherapeuticsNASDAQ:SYREView All Competitors FSTX Stock Analysis - Frequently Asked Questions How were F-star Therapeutics' earnings last quarter? F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.06. The company earned $0.75 million during the quarter, compared to the consensus estimate of $7.18 million. This page (NASDAQ:FSTX) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe #1 Crypto for 2024InvestorPlaceThe Greatest Bull Market in Crypto History…Weiss RatingsA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F-star Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.